# Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region

> **NCT01800006** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2101 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT01800006
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-14
- **Primary completion:** 2016-01-16
- **Final completion:** 2016-06-20
- **Target enrollment:** 2101 (ACTUAL)
- **Last updated:** 2017-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01800006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01800006, "Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01800006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*